132 related articles for article (PubMed ID: 35655188)
1. Gastrointestinal/genitourinary perforation and fistula formation with or without bevacizumab in patients with previously irradiated recurrent cervical cancer: a Korean multicenter retrospective study of the Gynecologic Oncology Research Investigators Collaboration (GORILLA) group (GORILLA-1001).
Hwang WY; Chang SJ; Kim HS; Kim NK; Kim TH; Kim Y; Kong TW; Lee EJ; Park SJ; Shim SH; Son JH; Suh DH; Yang EJ
BMC Cancer; 2022 Jun; 22(1):603. PubMed ID: 35655188
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab is associated with a higher gastrointestinal/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy.
Yang ST; Liu HH; Liu CH; Wang LW; Wang PH
Int J Gynaecol Obstet; 2024 May; ():. PubMed ID: 38746971
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab-associated events in Japanese women with cervical cancer: a multi-institutional survey of Obstetrical Gynecological Society of Kinki district, Japan.
Mabuchi S; Yamamoto M; Murata H; Yokoe T; Hamanishi J; Terai Y; Imatake H; Mabuchi Y; Mori T; Kitada F; Hashiguchi Y; Takahashi A; Fujiwara S; Naoi H; Matsubara S
Int J Clin Oncol; 2021 Mar; 26(3):598-605. PubMed ID: 33185777
[TBL] [Abstract][Full Text] [Related]
4. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
Redondo A; Colombo N; McCormack M; Dreosti L; Nogueira-Rodrigues A; Scambia G; Lorusso D; Joly F; Schenker M; Ruff P; Estevez-Diz M; Irahara N; Donica M; Gonzalez-Martín A
Gynecol Oncol; 2020 Oct; 159(1):142-149. PubMed ID: 32763109
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
[TBL] [Abstract][Full Text] [Related]
6. Incidence of fistula occurrence in patients with cervical cancer treated with bevacizumab: data from real-world clinical practice.
Sugiyama T; Katsumata N; Toita T; Ura M; Shimizu A; Kamijima S; Aoki D
Int J Clin Oncol; 2022 Sep; 27(9):1517-1528. PubMed ID: 35760943
[TBL] [Abstract][Full Text] [Related]
7. Hypoalbuminemia is a Predictive Factor for Fistula Formation in Recurrent Cervical Cancer.
Palavalli Parsons LH; Roane B; Manders DB; Richardson DL; Kehoe SM; Carlson M; Miller DS; Lea JS
Am J Clin Oncol; 2018 Oct; 41(10):933-937. PubMed ID: 28817390
[TBL] [Abstract][Full Text] [Related]
8. Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer.
Kim N; Choi SH; Chang JS; Kim YT; Kim SW; Kim GM; Kim YB
Int J Gynecol Cancer; 2021 Jan; 31(1):59-65. PubMed ID: 33273018
[TBL] [Abstract][Full Text] [Related]
9. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study.
Sfakianos GP; Numnum TM; Halverson CB; Panjeti D; Kendrick JE; Straughn JM
Gynecol Oncol; 2009 Sep; 114(3):424-6. PubMed ID: 19552944
[TBL] [Abstract][Full Text] [Related]
10. Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy.
Sturdza A; Hofmann S; Kranawetter M; Polterauer S; Grimm C; Krainer M; Kirisits C; Pötter R; Reinthaller A; Schwameis R
Strahlenther Onkol; 2017 Dec; 193(12):1056-1065. PubMed ID: 28721510
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study.
Chu G; Liu X; Yu W; Chen M; Dong L
BMC Cancer; 2021 Feb; 21(1):133. PubMed ID: 33549065
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
[TBL] [Abstract][Full Text] [Related]
15. Effect of addition of bevacizumab to chemoradiotherapy in newly diagnosed stage IVB cervical cancer: a single institution experience in Korea.
Youn SH; Kim YJ; Seo SS; Kang S; Lim MC; Chang HK; Park SY; Kim JY
Int J Gynecol Cancer; 2020 Jun; 30(6):764-771. PubMed ID: 32276937
[TBL] [Abstract][Full Text] [Related]
16. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
Richardson DL; Backes FJ; Hurt JD; Seamon LG; Copeland LJ; Fowler JM; Cohn DE; O'Malley DM
Gynecol Oncol; 2010 Jul; 118(1):47-51. PubMed ID: 20382413
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab does not increase risk of perforation in patients undergoing percutaneous endoscopic gastrostomy or jejunostomy placement.
Dibba P; Ludwig E; Calo D; Gerdes H; Markowitz A; Shike M; Schattner M; Mendelsohn R
Surg Endosc; 2021 Jun; 35(6):2976-2980. PubMed ID: 32583069
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab-related gastrointestinal perforation in patients with three or more prior chemotherapy regimens: A real-world experience.
Matsumiya H; Todo Y; Yamazaki H; Shimada C; Minobe S; Kato H
Taiwan J Obstet Gynecol; 2020 May; 59(3):377-380. PubMed ID: 32416883
[TBL] [Abstract][Full Text] [Related]
19. Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma.
Diaz JP; Tew WP; Zivanovic O; Konner J; Sabbatini PJ; dos Santos LA; Abu-Rustum NR; Chi DS; Aghajanian C; Barakat RR
Gynecol Oncol; 2010 Mar; 116(3):335-9. PubMed ID: 20004956
[TBL] [Abstract][Full Text] [Related]
20. Triplet chemotherapy vs doublet chemotherapy plus bevacizumab in metastatic, recurrent, and persistent cervical cancer.
Choi HJ; Lee YY; Choi CH; Kim TJ; Lee JW; Bae JH; Bae DS; Kim BG
Curr Probl Cancer; 2020 Oct; 44(5):100557. PubMed ID: 32067746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
